GlassScriptPhysician profile
Henry N Chionuma
NPI 1457355380
$327.92
in general payments reported to CMS, 2019-2025
11 companies · $30.60 in 2025
The $30.60 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $62.83 · 2021: $19.36 · 2022: $47.78 · 2023: $14.92 · 2024: $28.96 · 2025: $30.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.38 | 2022-2024 | Trulance, Xifaxan |
| Novo Nordisk INC | $46.36 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.25 | 2019 | |
| Sanofi Pasteur INC. | $40.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.89 | 2024-2025 | Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $26.18 | 2020 | |
| Allergan, INC. | $21.83 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.82 | 2020 | |
| Abbott Laboratories | $14.51 | 2022 | |
| Inspire Medical Systems, INC. | $14.48 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Chionuma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.